Peter Wijngaard, Director at Hepion Pharmaceuticals, Inc. (HEPA), bought 10,000 shares at $2.20 ($22K) on 2021-02-16, disclosed to the SEC on 2021-02-18.
Open-market purchase of $22k HEPA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| HEPA | BUY | 2020-12-21 | $38K | — | Filing → |